Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Best wishes all...and talking bout wishfull thinking: perhaps Reliance Industries sheds light on a future of shopping for proven authentic stuff...someday.
asias-richest-man-unveils-online-store-in-challenge-to-amazon
Colorcon, Inc. Launches On-Dose Authentication Platform From Applied DNA Sciences
STONY BROOK, N.Y., December 23, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions and nucleic acid-based biotherapeutic development, announced today that its partner, Colorcon, a world leader in the development and supply of film coating systems and excipients, formally launched the On-Dose Authentication capability to provide track and trace functionality for supply chain security. The seamless integration of molecular taggants from Applied DNA Sciences (ADNAS) into an Opadry® fully formulated film coating system significantly reduces the risks associated with counterfeit and falsified medications entering the supply chain.
This first commercial offering is the culmination of extensive collaboration between Colorcon and ADNAS to help pharmaceutical companies enhance patient safety and reduce risk by using intelligent data and analytics gathered from authentication of the dosage form itself. By better understanding the vulnerabilities of a complex global supply chain, drug manufacturers can make informed decisions regarding distribution networks and deploy preventative measures to address counterfeiting and product diversion issues.
Dr. Ali Rajabi-Siahboomi, Vice President/Chief Scientific Officer at Colorcon Inc. says, “With new guidelines from regulators and accessible technology, on-dose solutions provide a more robust and reliable means of identifying and deterring counterfeiting, verifying product authenticity, and ensuring product traceability. Through extensive research and development, Colorcon has created a unique coating system to address this global problem.”
Kelly Boyer, General Manager, Film Coatings at Colorcon Inc. explains, “On-dose authentication technology represents the next generation in pharmaceutical supply-chain security by providing a powerful tool for tracking product from plant to patient. By seamlessly enabling authentication, these digitized coatings confirm the quality and origin of medicines thereby safeguarding both patients and brands.”
Colorcon continues to advance technologies and services to meet industry challenges with innovative solutions. This latest technology yet again demonstrates Colorcon’s leadership in responding to the needs of the pharmaceutical industry, bringing novel solutions that are efficient to deliver with dependable performance.
Didnt we have a a cellulosic fiber patent something...
adhoc-the-decision-has-been-made-lenzing-joint-venture-to-build-dissolving-pulp-plant-in-brazil
Tetrapak and fully traceable biopolymers in packaging? Why not with CertainT?
Tetra-Pak-Becomes-the-First-Company-in-the-Food-and-Beverage-Industry-to-Offer-Packaging-Made-With-Fully-Traceable-Plant-based-Polymers
Hmmm....
How about Honeywell Arespace parts bei g tagged by Securemarking in coop with iTrace...honeywell-itrace-and-securemarking-combat-counterfeit-activity-in-aerospace-with-blockchain
Really wondering what nanoparticle ink they use being a nonclonable identifier...
Perhaps former Honeywell Gordon Hope can shed light?
This must be SignatureDNA right?
Is our golden standard yet again (alegedly) adopted by another tagntrace company? Is CertainT a mere showcase for what other anticounterfeit and IP protecting companies can do with it(forensically)?...or are we truely outpaced and surpassed yet again by a competitor? The latter I cannot believe so I won't.
Lets start tagging some more hemp, period...the material deserves it:
hemp according to Material Conexxion
Very reensuring knowing we have more cannabis stuff going on besides Theracann...
I think this: in the agreement there has been a clausule providing Theracann exclusivity as long as SignatureDNA is the only tagntrace provider...the moment Theracann also onboarded Tagit Tech (and Trutags along with them), the exclusivity was gone, hence also the exclusive licensing fee.
I think we didnt lose Theracann, but we are now just part of a multilayered ETCH Biotrace approach.
CMtrex and Cannacubed mi g ht very well still be in range....thoufht anyone?
Yeah Mickeyboy...we're in good company with RIL.
Enabling plastic industry and governments to prove recycling and even assessing % recycled PET is BIG
There are fewer and fewer enthoused longs?
Stocktwits is relatively "busy" lately.
Thought a question bout ownership of LinearX at the last conferencecall was answered by Hayward affirming such %... but I could be wrong
Doubt that...haelixa is spinoff eth zurich where Robert Grass has been researching in silica embedded dna as well as turbobeads (magnetic coating for extracting it from fluids like oliveoil) for ages. Although it could somehow explain the organic cotton hickup for adnas SignatureDNA possibly not eligible as an organic supplement?
Never understood why an obvious link between him (Grass) and adnas never surfaced...isnt it there?
Haelixa I mentioned way back 2016 or 2017 I think already
Some clarification would be nice on how adnas relates to different but sortlike approaches...
Colorcon just released this whitepaperimplementing-on-dose-authentication-technologies-for-solid-dose-drug-products
offering both adnas and trutag to their customers...
Just request and download via the link
At Stocktwits there was mention of Adnas no longer on the noncompliant list...
Meanwhile in Organic Cotton:
successfully-tracing-organic-cotton-with-innovative-technologies where a competitive approach resembles adnas' one a lot.
Seems Robert Grazz' work at ETCH has found its commercialisation.
Questions are: What is the reason Haelixa was contracted back in 2018? Organic cotton was an Adnas hickup wasnt it McShark?
And again...is this a competitor like Trutag and Safetraces seem to be, or is some sort of licensing of adnas tech in the equation somewhere?
How you explain Colorcons productmanager Daniel To positively previewing his presentation at AAPS PharmSci 360 2019 3 weeks ago....shared at LinkedIn in a video?
See below (or through this link (and search for Daniel To) the recap of his presentation:
Trutag for just the seed seems plausible...yes?
Spraying the plant SignatureDNA remains traceable even after processing to flowers, butter, oil, fiber, cake, tea, coke (cola) etc right?
Somehow I think Trutags havent been tested through this processing?
In silica embedded dna... could signaturedna be embedded in/ by trutags insilica tags?
It could explain some coincidental shared customers...
Trutags Mike. Oh my....
#@!f..*(¥ G
In addition we had an Evotec order to test the linearx dna...and Evotec also had some LAB555news the other day, with an Israelian link as well:evotec-integra-holdings-and-yissum-establish-lab555-to-fast-track-early-stage-drug-development
Adnas' cryptotech is quantumproof right?quantum supremecy ??
Applied DNA Receives Notice of Allowance on Patent Protecting its CertainT® Platform in Cellulosic Fibers and Materials
Newly Allowed Patent Covers use of the CertainT ® Platform in Cellulosic Fibers and Materials including Rayon; Company Currently in Discussions with Leading Manufacturers
STONY BROOK, N.Y. – October 22, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced today that it has received a Notice of Allowance for its U.S. Patent Application No. 15/466,016 (US 2017/0292206) entitled “Methods of Marking Cellulosic Products.” The allowed patent application, which is expected to be issued as a U.S. patent in the next few months, extends the Company’s patent protection for its CertainT platform into cellulosic fibers and materials. The Company has related international patent applications pending in India, the European Union, China and Hong Kong.
The allowed claims cover methods of tagging cellulosic fibers or materials with a nucleic acid (DNA) tag during production and later authenticating the nucleic acid-tagged cellulosic fibers and/or materials via PCR-based detection techniques.
Cellulosic fibers and materials are man-made and are derived from plant-based resources (cellulose). Notable cellulosic fibers and materials include rayon. The demand for cellulosic fibers and materials is rapidly expanding, with a market size estimated to surpass USD 39 billion by 2024, growing at an annual rate of 9%[1].
“We are in commercial stage discussions with some of the world’s largest cellulosic fiber and materials manufacturers for the implementation of our proven CertainT platform,” said Dr. James Hayward, president and Chief Executive of Applied DNA. “The newly allowed patent is a significant milestone for the Company as it enhances our intellectual property portfolio and provides potential exclusivity for our CertainT platform in the ever-growing cellulosic fiber and materials market.”
Dr. Hayward continued: “Since many man-made cellulosic materials such as rayon (with component fibers known as lyocell, viscose and modal) are derived from trees, traceability to assure brand claims for responsible sourcing and sustainable claims is important. The CertainT solution assists fiber producers in ensuring the authenticity and traceability of their branded fibers. We have successfully demonstrated the robust performance of the CertainT molecular tag in commercial production environments from fiber to fabric with top-tier rayon manufacturers in both home goods and apparel.”
I didnt make it to K2019 this year, and I dont think Adnas was again chapperoning Techmer there like in 2016. What I do find is this recent newsflash...indicating we are, via Techmer, still or at last much alive in plastic track n trace techmer-pm-expands-its-sustainable-solutions-portfolio
sc-johnson-plastic-bank-global-partnership-fight-ocean-plastic-and-poverty
Social Plastic perhaps?
Digimarc with Berry Global seems to have Ellen McArthurFoundation partners (with PG in the lead) enthused and piloting plastic sorting tech aiding recycling....is CertainT adding value? Or are we focussing on testing SignatureDNA in combo with Ioniqas breakdown tech launched with Indorama and Unilever linkand others too like LyondellBasel with KIT link too in a similar way, have developed? Where is our tech adding value? BASF's tech along with mass balance approach???Or will we replace it all when realtime scanning our dna will finally happen in mSecs DREAM
I think we need polymer and PET updates ! And some cannabis, textile and pharma news would be welcome too...asap
SGS partnered with Natures Fingerprints in 2017 :
sgs-partners-with-natures-fingerprint-to-beat-pharmaceutical-counterfeiting
Applied DNA Partners with Molecular Isotope Technologies to Elevate CertainT® for Brand Assurance and Provenance
CertainT Platform Complemented by Stable-Isotopic Indicators Offers Brand Owners Increased Supply Chain Transparency and Product and Process Authentication
STONY BROOK, N.Y. – October 16, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”, the “Company”), a leader in polymerase chain reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced today that it has entered into a partnership with Molecular Isotope Technologies, LLC (“MIT LLC”), a pioneer and leader in the application of natural-abundance stable-isotopic analysis provided under the trademarks Nature’s Fingerprint® and IsoPedigree™. MIT LLC’s technology utilizes stable isotopic "fingerprints" as a method for verification of product origin and supply chain processing to support product claims.
For 20 years MIT LLC has provided patented services to the bio/pharmaceutical industry which have been successfully employed in various legal matters, supporting pharmaceutical patent-infringement and fraud lawsuits. These authentication services are tailored to specific product and supply chain processes and will be offered by Applied DNA as an additional component of its CertainT® platform to tag, test and track raw materials and finished goods. MIT LLC will support and promote the CertainT platform as a service complementary to its own.
“Through the combined power of our cutting-edge technologies, Applied DNA offers brand owners “one-stop-shop” access to unique analytical tools to verify product and process authenticity for brand assurance and provenance with forensic certainty. This partnership with MIT LLC enhances Applied DNA’s CertainT feature-set by offering additional datapoints for deeper product and supply chain intelligence supported by world-class forensic laboratory services. The large-scale tagging and authentication of customer-specific DNA identity at most any supply chain node, combined with genotyping identification allies perfectly with stable-isotopic identification of origin and process. We expect our enhanced portfolio will serve to further our penetration of key markets such as textiles, adding another level of identity for organic cotton, among other natural materials,” stated Judy Murrah, chief information officer of Applied DNA.
Dr. John P. Jasper, chief scientific officer and founder of MIT LLC, said, “Our partnership with Applied DNA offers great specificity in forensic authentication to our joint customers, amplifying product and process claims throughout highly complex global supply chains. Nearly 40 years of work in this area of natural-abundance stable-isotope science and service across several industries has led to a deep knowledge and insight into the chemistry which has evolved into patented processes for protecting intellectual-property and product claims.”
Stable-isotopic “fingerprints” within materials provide innate chemical evidence of their chemical, geographic, and industrial provenance and major processing-dependent characteristics. They derive from the natural abundance of various stable isotopes including carbon, nitrogen, oxygen, sulfur and others that vary in their isotopic ratios and are present in soil, water and other organic materials and become integrated with the chemical composition of a product from raw materials through synthetic intermediates to finished products. Discrete process steps may alter isotopic fingerprints, permitting the identification of deviations in locale or materiel. MIT LLC’s existing and pending patents variously encompass the use of natural-abundance stable-isotopic analysis for establishing both product and process fingerprints.
About Molecular Isotopes Technologies, LLC
Founded in 1999, Molecular Isotope Technologies (MIT LLC) owns and uses the trademarks Nature’s Fingerprint® and IsoPedigree™. Via highly precise natural-abundance stable-isotopic analysis, MIT LLC significantly contributes to the definition of intellectual-property provenance and to the mitigation of intellectual-property infringement of various organic (e.g., bio/pharmaceutical, agricultural, and other) products and the synthetic pathways by which they were produced. After having established the isotopic provenance and process pathways of various bio/pharmaceutical materials, MIT LLC has provided the isotopic evidence that has protected more than $2 billion of bio/pharmaceutical products.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and isolation of circulating tumor cells and the development of pre-clinical nucleic acid-based therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its ability to continue as a going concern, its history of net losses, limited financial resources, limited market acceptance, uncertainties relating to its ability to maintain its NASDAQ listing in light of delisting notices received and its recent hearing, our ability to penetrate key markets, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
INVESTOR CONTACT
Sanjay M. Hurry, LHA Investor Relations
212-838-3777, shurry@lhai.com
PROGRAM CONTACT
Judy Murrah, Chief Information Officer
631-240-8819, judy.murrah@adnas.com
Facebook ? Twitter ? LinkedIn ?
Applied DNA Sciences
50 Health Sciences Drive
Stony Brook, NY 11790
Unsubscribe info@vanpoppelconsultancy.nl
Update Profile | About Constant Contact
Sent by heather.berry@adnas.com
in collaboration with
Trusted Email from Constant Contact - Try it FREE today.
Try email marketing for free today!
BASF invests in Quantafuel to drive chemical recycling of plastic waste
Molecular Tagging of Pharmaceutical Excipients Utilizing Applied DNA’s Technology Published in Peer-Reviewed Journal
International Journal of Pharmaceutics publication evaluates a proprietary method to tag pharmaceutical excipients. Study conducted at King’s College London with Collaborators from Dubai Police and Applied DNA concludes the proprietary method of DNA tagging excipients can mitigate the risks of counterfeit drugs.
STONY BROOK, N.Y., October 4, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that a scientific paper entitled, ‘Anti-counterfeiting DNA molecular tagging of pharmaceutical excipients: An evaluation of lactose containing tablets’, has been published in the International Journal of Pharmaceutics, detailing a novel Physical-Chemical Identifier (PCID) to authenticate and track legitimate pharmaceutical products through the pharmaceutical supply chain.
The study carried out by a team led by Dr. Royall at the Institute of Pharmaceutical Science, King’s College London and Dr. Altamimi from the Department of Forensic Evidence & Criminology, Dubai Police HQ, UAE, evaluated the use of DNA molecular tags as a potential anti-counterfeiting technology in tablets. Lactose tablets were used as a model of a solid dosage form. Analysis for in-field DNA authentication was carried out using a portable Applied DNA SigNify® qPCR instrument. Tablet batches were subjected to accelerated stability conditions for 6 months with the DNA tag clearly detected in all tablets after the storage period. All tablet batches passed the monograph specifications of the British Pharmacopoeia throughout the storage period. The study concluded that DNA molecular tags could feasibly be applied within the pharmaceutical development cycle when a new solid dosage form is brought to the market so as to mitigate the risk and dangers of counterfeiting.
“We believe DNA tagging of inks, coatings, and other ingredients are candidates for use in the pharmaceutical supply chain, securing authenticity of an individual tablet or capsule from the manufacturer, to the distributor, and finally the pharmacy. We believe authentication is possible, even when the product is separated from packaging, making it a complement to serialization and a platform to be considered as a weapon against today’s most difficult and global challenges, such as the opioid crisis,” said Dr. James Hayward, president and CEO, Applied DNA.
The licensed pharmaceutical industry and regulators use many approaches to control counterfeiting, but it remains a very difficult task to differentiate between counterfeit and real products. Moreover, there is a lack of techniques available for providing a batch-specific molecular bar code for tablets and other solid oral dosage forms that require traceability, specificity and sensitivity to be fit for purpose.
“Counterfeit drugs represent a large and growing problem for the global pharmaceutical industry and can lead to serious illness or death. Publication of our methods and systems for molecular tagging of pharmaceuticals is a seminal development in our industrial deployment, and acceptance of our methods by scientific peers is a welcome endorsement,” said Dr. Michael Hogan, vice president, Life Sciences, Applied DNA.
“Many tablets contain lactose; thus, it was sensible to use this popular excipient in our proof of concept study. Lactose presented a good challenge to Applied DNA’s technology as it is a reducing sugar and in combination with the high temperature and high humidity storage conditions, it formed a harsh environment to test the stability of the molecular tags. The DNA tags performed exceptionally well, and were able to be easily detected after six months of storage. We believe this study shows the potential of the technology to provide traceability beginning with the powdered ingredients right through to the fully formed medicine,” said Dr. Paul Royall, Senior Lecturer in Pharmaceutics, King’s College London.
About the Institute of Pharmaceutical Science, King’s College London
The Institute of Pharmaceutical Science at King’s College London is part of the Faculty of Life Sciences & Medicine. The Institute has a flourishing research effort in the fields of drug discovery, medicines development and medicines use, and has approximately 100 registered postgraduate research students. Through the Department of Pharmacy, the Institute provides initial education and training for pharmacists through the MPharm program and provides a range of specialist postgraduate taught courses in Pharmaceutical Science, Pharmaceutical Medicine and Clinical Pharmacy.
Applied DNA Receives Extension from Nasdaq
STONY BROOK, N.Y., October 3, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”) (“we,” “us,” “our,” the “Company”), a leader in large-scale PCR-based DNA manufacturing, today announced that the Nasdaq Hearings Panel (the “Panel”) , has granted Applied DNA’s request for an extension through December 31, 2019, to comply with all applicable criteria for continued listing of the Company’s securities on The Nasdaq Capital Market (“Nasdaq”), including the minimum $1.00 bid price and $2.5 million stockholders’ equity requirements. During the extension, Applied DNA’s securities will remain listed on Nasdaq.
“We are appreciative of the Nasdaq Hearings Panel’s decision to grant us our requested extension to evidence compliance with all applicable requirements for continued listing on Nasdaq. The management team and Board of Directors place the highest priority on our continued listing, and we want to assure all stakeholders that we continue to work diligently on executing on our compliance plan,” stated Dr. James A. Hayward, president and CEO of Applied DNA.
The Company is diligently working to comply with the minimum $1.00 bid price and $2.5 million stockholders’ equity requirements; however, there can be no assurance that the Company will be able to regain compliance with the applicable listing criteria within the period granted by the Panel.
Interesting news...very interesting
I think Evotecs and Takedas partnering in drugdiscovery (e.g oncology and rare disease) is interesting....
Tumor Reduction Demonstrated In Vivo Using Two Linear DNA Vaccines in Animal Models
STONY BROOK, N.Y., September 19, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its majority-owned subsidiary focused on next-generation biotherapeutics, and its collaborators Takis/Evvivax have completed pre-clinical animal studies of two vaccine candidates produced with linear DNA. Tests of both vaccines in mouse models demonstrated their ability to eliminate tumors in vivo, and to potentially prevent initial occurrence.
Evvivax S.R.L. designed a synthetic gene sequence to produce immunity in companion animals, directed against the protein telomerase (TERT), which is overexpressed in 85% of all mammalian cancers, whereas Takis S.R.L. designed a neoantigen-based cancer vaccine (TK), as a proof-of-concept of personalized immunology. For the studies, the TERT and TK based vaccines were produced in linear DNA form by LineaRx. Here is a summary of the recently completed studies performed in vivo:
Previous results from Phase 1 of the collaboration’s Joint Development Agreement (JDA) confirmed immunogenicity in mice that were vaccinated with linear DNA against the human protein telomerase. The results reported herein are from the Phase 2 of the JDA using mice implanted with murine colon cancer.
In the prophylactic use of the telomerase vaccine, wherein vaccination is done before addition of tumor cell lines to the mice, transplanted tumors were cleared within 10 days.
In the therapeutic application using either TERT or TK linear DNA vaccine application, cancer cells were introduced and allowed to grow before administration of the vaccine. The successful reduction of total tumor mass was accomplished in conjunction with antibodies that targeted PD-1 and CTLA4. These antibodies, known as Checkpoint Inhibitors, are commonly used in oncology strategies that rely upon immunotherapy. In this setting the tumor cells were reduced significantly within 30 days.
The strategy of the Takis TK neoantigen vaccine uses unique multiple-target antigenic epitopes that have been identified from the tumor of a human patient. The linear DNA can utilize the genes for several of the most effective universal antigens such as TERT, or neoantigens that are more personalized to the patient.
“We know that immune system has a key role in fighting cancer” said Dr. Luigi Aurisicchio, CEO of Takis/Evvivax. “Thanks to a deep knowledge of cancer immunobiology and cutting-edge vaccination technologies we have now the tools to provide new therapies to our pet friends and human patients.”
“Our unique triumvirate of JDA partners is compelling, in that clinical data accumulated from linear DNA vaccines for companion animals can be used to accelerate translation to human therapies by Evvivax and Takis” said Dr. James Hayward, president and CEO of Applied DNA and LineaRx. “Cancer vaccines would extend the lives of many family pets, and the benefit we believe would rapidly enure to humans.”
Linear DNA vaccines are being spearheaded by LineaRx to drive more efficient production methods and what are believed to be safer therapies for patients. Current production standards for human DNA vaccines use the circular DNA of plasmids that are grown in bacteria. However, this raises concerns regarding the risk of integration of bacterial genes including the antibiotic-resistance genes into the human genome or transfer into commensal bacteria, that are a normal part of the human bacterial flora.
Dr. Aurisicchio concluded, “The advantages of linear DNA should improve the safety and efficacy of all gene therapies, both in animals as well as humans.” The JDA partners expect to publish their results in the scientific literature soon and will initiate planned Phase 3 work in companion animals.
lenzing-presented-first-blockchain-pilot-project
Certainly hope so adnas is amongst those other partners to complete Lenzings traceability efforts...
Stay safe my friend
Thanks Mike !
Awaiting news and more, I thought to share a brief 20th century-history from dutch perspective of pot:https://www.leafly.com/news/growing/history-dutch-marijuana-seed-banks" rel="nofollow" target="_blank" >history-dutch-marijuana-seed-bank